ERBB2 and breast cancer: Another retrospective study, involving 40% (43/107) of early HER2-positive BC patients receiving adjuvant trastuzumab determined that a high NLR was associated with notably lower survival rates only in the subgroup of HER2-positive patients not treated with trastuzumab, but not in the subgroup of patients who were treated with trastuzumab [14].